Amaru R, Quispe T, Miguez H, Torres G, Peñaloza R, Amaru A, Cuevas H

Language: Spanish
References: 21
Page: 281-287
PDF size: 532.19 Kb.

ABSTRACT

Background: Myelodysplastic syndrome is a clonal disease of hematopoietic stem cells, and it is frequent in patients over the age of 60. It is characterized by an ineffective hematopoiesis, leading to progressive cytopenias. Studies carried on peripheral blood and bone marrow samples displayed cytopenias, dishematopoyesis and blasts in any of the myeloid lineages. According to WHO and IPSS-R system, a complete blood count, morphological studies of both bone marrow and peripheral blood, blasts percentage, cytochemical study (Perls) and a cytogenetic study are required in order to provide an adequate classification and prognosis.
Objective: To describe the results using a standard method including fluorescent in situ hybridization in samples of patients with myelodysplastic syndrome in Bolivia.
Material and method: A retrospective study was done identifying 52 cases of mielodysplastic syndrome from several cities of Bolivia, without personal history of chemotherapy or radiotherapy. The cases studied were diagnosed from January 2014 to September 2015 and samples were sent to Cell Biology Unit of Universidad Mayor de San Andrés, Bolivia.
Results: Patients older than 60 years presented an increased number of cases, reflecting a predominance of female gender. The most common cytogenetic abnormalities were del(20q), del(5q) and trisomy-8. These results are characteristic of Bolivian region since the frequency of cytogenetic abnormalities is different compared to studies reported in Brazil, Japan and the United States.
Conclusion: One to three cytogenetic disorders were identified in 44% of the analyzed samples. This figure agrees with that reported in scientific literature.

REFERENCES

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885.

2. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011;29:516-523.

3. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.

4. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndrome: real or factitious? Int J Hematol 2001;73:405-410.

5. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.

6. Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012;120:2076-2086.

7. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-1325.

8. West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a casecontrol study. Leuk Res 1995;19:127-139.

9. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993;7:1975-1986.

10. Valent P, Horry HP, Bennet JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-736.

11. Rund D, Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology 2004;9:179-187.

12. Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 2001;14:479-495.

13. Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anaemia in myelodysplastic syndromes. Blood 2005;106:2633-2640.

14. Qu S, Xu Z, Zhang Y, et al. Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study. Leuk Lymphoma 2012;53:940-946.

15. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.

16. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-829.

17. Greenberg PL, Attar E, Bennett JM, et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013;11:838-874.

18. Borgonovo T, Ribeiro E, Cornélio D, et al. Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS). Genetics Molecular Biol 2005;28:654-660.

19. Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005;106:2633-2640.

20. Fenaux P, Haase D, Sanz GF, Santini V, Buske C. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:57-69.

21. Jaffe ES, Harris NL, Stein H, et al. (eds). World Health Organization classification of tumours, pathology and genetics of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008;75-104.